3-(2-propoxy-2-methylpropyl)-2-thioxanthine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并嘧啶类
• 英文名称: 3-(2-propoxy-2-methylpropyl)-2-thioxanthine
• 英文别名: 3-(2-methyl-2-propoxypropyl)-2-sulfanylidene-7H-purin-6-one
• 化学式: C₁₂H₁₈N₄O₂S
• 分子量: 282.367
• InChiKey: HHCAUZJXLFBINI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  19
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.58
• 拓扑面积：
  102
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  2-methyl-2-propoxypropionaldehyde 在 sodium cyanoborohydride 、 溶剂黄146 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 反应 7.0h， 生成 3-(2-propoxy-2-methylpropyl)-2-thioxanthine
  参考文献：
  名称：

  WO2007/142576

  摘要：

  公开号：

文献信息

• Compounds
  申请人：Tiden Anna-Karin

  公开号：US20080221133A1

  公开（公告）日：2008-09-11

  The present invention relates to a compound according to Formula (I) wherein R 1 is selected from C 1 -C 6 alkyl, and said C 1 -C 6 alkyl is substituted with C 1 -C 6 alkoxy; and at least one of said C 1 -C 6 alkyl or said C 1 -C 6 alkoxy is branched; or a pharmaceutically acceptable salt thereof, solvate or solvate of a salt thereof, as well as, to compositions containing at least one compound according to Formula (I) and methods of treating at least one disease or condition therewith.

  本发明涉及一种化合物，其化学式为（I）式，其中R1选自C1-C6烷基，所述C1-C6烷基被C1-C6烷氧基取代；且所述C1-C6烷基或所述C1-C6烷氧基中至少有一个是支链的；或其药学上可接受的盐、溶剂或其盐的溶剂，以及至少含有一种化合物（I）的组合物和使用该组合物治疗至少一种疾病或病况的方法。
• 2 thioxanthine derivatives acting as MPO-inhibitors
  申请人：AstraZeneca AB

  公开号：US07943625B2

  公开（公告）日：2011-05-17

  The present invention relates to a compound according to Formula (I) wherein R1 is selected from C1-C6 alkyl, and said C1-C6 alkyl is substituted with C1-C6 alkoxy; and at least one of said C1-C6 alkyl or said C1-C6 alkoxy is branched; or a pharmaceutically acceptable salt thereof, solvate or solvate of a salt thereof, as well as, to compositions containing at least one compound according to Formula (I) and methods of treating at least one disease or condition therewith.

  本发明涉及公式（I）中的化合物，其中R1选自C1-C6烷基，所述C1-C6烷基被C1-C6烷氧基取代；且所述C1-C6烷基或所述C1-C6烷氧基中至少有一个是支链；或其药学上可接受的盐、溶剂或其盐的溶剂，以及至少含有公式（I）中的一种化合物的组合物和用于治疗至少一种疾病或病况的方法。
• 2-Thioxanthine Derivatives Acting as MPO-Inhibitors
  申请人：Tiden Anna-Karin

  公开号：US20090131459A1

  公开（公告）日：2009-05-21

  The present invention relates to a compound according to Formula (I) wherein R 1 is selected from C 1 -C 6 alkyl, and said C 1 -C 6 alkyl is substituted with C 1 -C 6 alkoxy; and at least one of said C 1 -C 6 alkyl or said C 1 -C 6 alkoxy is branched; or a pharmaceutically acceptable salt thereof, solvate or solvate of a salt thereof, to compositions containing the compound and the use thereof in therapy.

  本发明涉及一种化合物，其化学式为(I)，其中R1选自C1-C6烷基，所述的C1-C6烷基被C1-C6烷氧基取代; 并且所述的C1-C6烷基或所述的C1-C6烷氧基中至少有一个是支链的; 或其药学上可接受的盐，溶剂或其盐的溶剂，以及包含该化合物的组合物和其在治疗中的用途。
• 2-THIOXANTHINE DERIVATIVES ACTING AS MPO-INHIBITORS
  申请人：Astra Zeneca AB

  公开号：EP2029598A1

  公开（公告）日：2009-03-04
• METHODS OF TREATING COMPLICATIONS AND DISORDERS ASSOCIATED WITH G-CSF ADMINISTRATION
  申请人：SACKSTEIN Robert

  公开号：US20130224217A1

  公开（公告）日：2013-08-29

  The present embodiments relate to novel uses of MPO inhibitors and inhibitors of MPO and E-selectin binding. In some embodiments, methods are provided for treating G-CSF-induced vascular complications and associate tissue injury comprising administering to a subject in need thereof a compound that inhibits E-selectin receptor/ligand interaction or inhibits MPO activity. The inhibitors may be administered in conjunction with G-CSF therapy. The inhibitors include antibody molecules, as well as homologues, analogues and modified or derived forms thereof, including immunoglobulin fragments like Fab, F(ab′) 2 and Fv, small molecules, including peptides, oligonucleotides, peptidomimetics (including aptamers) and organic compounds (e.g., glycomimetics).